메뉴 건너뛰기




Volumn 22, Issue 6, 2015, Pages 484-488

T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplant; CD123; Hematopoiesis

Indexed keywords

CD123 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; IL3RA PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 84944080588     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0000000000000190     Document Type: Review
Times cited : (50)

References (37)
  • 1
    • 42449128875 scopus 로고    scopus 로고
    • Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002
    • Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control CCC 2008; 19:379-390.
    • (2008) Cancer Causes Control CCC , vol.19 , pp. 379-390
    • Yamamoto, J.F.1    Goodman, M.T.2
  • 3
    • 84874053507 scopus 로고    scopus 로고
    • The myth of the second remission of acute leukemia in the adult
    • Forman SJ, Rowe JM. The myth of the second remission of acute leukemia in the adult. Blood 2013; 121:1077-1082.
    • (2013) Blood , vol.121 , pp. 1077-1082
    • Forman, S.J.1    Rowe, J.M.2
  • 5
    • 84876095248 scopus 로고    scopus 로고
    • Acute myeloid leukemia in first remission: To choose transplantation or not?
    • Stone RM. Acute myeloid leukemia in first remission: To choose transplantation or not? J Clin Oncol Off J Am Soc Clin Oncol 2013; 31:1262-1266.
    • (2013) J Clin Oncol off J Am Soc Clin Oncol , vol.31 , pp. 1262-1266
    • Stone, R.M.1
  • 7
    • 3242754448 scopus 로고    scopus 로고
    • Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity
    • Hope KJ, Jin L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nat Immunol 2004; 5:738-743.
    • (2004) Nat Immunol , vol.5 , pp. 738-743
    • Hope, K.J.1    Jin, L.2    Dick, J.E.3
  • 8
    • 0033815950 scopus 로고    scopus 로고
    • The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells
    • Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia 2000; 14:1777-1784.
    • (2000) Leukemia , vol.14 , pp. 1777-1784
    • Jordan, C.T.1    Upchurch, D.2    Szilvassy, S.J.3
  • 9
    • 84904465235 scopus 로고    scopus 로고
    • Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
    • Frankel AE, Woo JH, Ahn C, et al. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood 2014; 124:385-392.
    • (2014) Blood , vol.124 , pp. 385-392
    • Frankel, A.E.1    Woo, J.H.2    Ahn, C.3
  • 10
    • 0035662980 scopus 로고    scopus 로고
    • Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies
    • Muñoz L, Nomdedéu JF, López O, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica 2001; 86:1261-1269.
    • (2001) Haematologica , vol.86 , pp. 1261-1269
    • Muñoz, L.1    Nomdedéu, J.F.2    López, O.3
  • 11
    • 28844456971 scopus 로고    scopus 로고
    • Hematopoietic stem cells express multiple myeloid markers: Implications for the origin and targeted therapy of acute myeloid leukemia
    • Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood 2005; 106:4086-4092.
    • (2005) Blood , vol.106 , pp. 4086-4092
    • Taussig, D.C.1    Pearce, D.J.2    Simpson, C.3
  • 12
    • 0034119046 scopus 로고    scopus 로고
    • Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias
    • Frankel AE, McCubrey JA, Miller MS, et al. Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia 2000; 14:576-585.
    • (2000) Leukemia , vol.14 , pp. 576-585
    • Frankel, A.E.1    McCubrey, J.A.2    Miller, M.S.3
  • 13
    • 0034886842 scopus 로고    scopus 로고
    • High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein
    • Alexander RL, Ramage J, Kucera GL, et al. High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001; 25:875-881.
    • (2001) Leuk Res , vol.25 , pp. 875-881
    • Alexander, R.L.1    Ramage, J.2    Kucera, G.L.3
  • 14
    • 84932085600 scopus 로고    scopus 로고
    • A Phase 1 study of the safety, pharmacokinetics and antileukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
    • He SZ, Busfield S, Ritchie DS, et al. A Phase 1 study of the safety, pharmacokinetics and antileukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma 2015; 56:1406-1415.
    • (2015) Leuk Lymphoma , vol.56 , pp. 1406-1415
    • He, S.Z.1    Busfield, S.2    Ritchie, D.S.3
  • 15
    • 84899137486 scopus 로고    scopus 로고
    • Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells
    • Nievergall E, Ramshaw HS, Yong ASM, et al. Monoclonal antibody targeting of IL-3 receptor a with CSL362 effectively depletes CML progenitor and stem cells. Blood 2014; 123:1218-1228.
    • (2014) Blood , vol.123 , pp. 1218-1228
    • Nievergall, E.1    Ramshaw, H.S.2    Yong, A.S.M.3
  • 16
    • 84929943283 scopus 로고    scopus 로고
    • First-in man, phase 1 study of CSL362 (anti-IL3Ra/anti-CD123 monoclonal antibody) in patients with CD123 acute myeloid leukemia (AML) in CR at high risk for early relapse [abstract]
    • Smith B, Roboz G, Walter R, et al. First-in man, phase 1 study of CSL362 (anti-IL3Ra/anti-CD123 monoclonal antibody) in patients with CD123 acute myeloid leukemia (AML) in CR at high risk for early relapse [abstract]. Blood 2014; 124:120.
    • (2014) Blood , vol.124 , pp. 120
    • Smith, B.1    Roboz, G.2    Walter, R.3
  • 17
    • 84904460162 scopus 로고    scopus 로고
    • CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
    • Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res 2014; 2:4.
    • (2014) Biomark Res , vol.2 , pp. 4
    • Testa, U.1    Pelosi, E.2    Frankel, A.3
  • 18
    • 84937399143 scopus 로고    scopus 로고
    • Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTS1)
    • Blood 2013
    • Hussaini MA, Ritchey J, Retting M, et al.: Targeting CD123 in leukemic stem cells using dual affinity re-targeting molecules (DARTs1) [abstract]. Proceedings of the 55th ASH annual meeting; 2013. Blood 2013; 122:360.
    • (2013) Proceedings of the 55th ASH Annual Meeting , vol.122 , pp. 360
    • Hussaini, M.A.1    Ritchey, J.2    Retting, M.3
  • 19
    • 84929956747 scopus 로고    scopus 로고
    • Immunotherapy with long-lived anti-CD123 - Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123 cells in monkeys: A potential therapy for acute myelogenous leukemia. Proceedings of the 56th ASH annual meeting
    • Chu S, Pong E, Chen H, et al. Immunotherapy with long-lived anti-CD123 - Anti-CD3 bispecific antibodies stimulates potent T cell-mediated killing of human AML cell lines and of CD123 cells in monkeys: A potential therapy for acute myelogenous leukemia. Proceedings of the 56th ASH annual meeting. Blood 2014; 124:2316.
    • (2014) Blood , vol.124 , pp. 2316
    • Chu, S.1    Pong, E.2    Chen, H.3
  • 20
    • 77956535599 scopus 로고    scopus 로고
    • Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor
    • Jena B, Dotti G, Cooper LJN. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010; 116:1035- 1044.
    • (2010) Blood , vol.116 , pp. 1035-1044
    • Jena, B.1    Dotti, G.2    Cooper, L.J.N.3
  • 21
    • 84877669593 scopus 로고    scopus 로고
    • The basic principles of chimeric antigen receptor design
    • Sadelain M, Brentjens R, Riviè re I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3:388-398.
    • (2013) Cancer Discov , vol.3 , pp. 388-398
    • Sadelain, M.1    Brentjens, R.2    Riviè, R.I.3
  • 22
    • 80051775476 scopus 로고    scopus 로고
    • T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
    • Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3:95-73.
    • (2011) Sci Transl Med , vol.3 , pp. 73-95
    • Kalos, M.1    Levine, B.L.2    Porter, D.L.3
  • 23
    • 84860718270 scopus 로고    scopus 로고
    • Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells
    • Scholler J, Brady TL, Binder-Scholl G, et al. Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 2012; 4:132-53.
    • (2012) Sci Transl Med , vol.4 , pp. 53-132
    • Scholler, J.1    Brady, T.L.2    Binder-Scholl, G.3
  • 24
    • 84876005284 scopus 로고    scopus 로고
    • CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
    • Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5:177-38.
    • (2013) Sci Transl Med , vol.5 , pp. 177-238
    • Brentjens, R.J.1    Davila, M.L.2    Riviere, I.3
  • 25
    • 84908073316 scopus 로고    scopus 로고
    • Chimeric antigen receptor T cells for sustained remissions in leukemia
    • Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371:1507- 1517.
    • (2014) N Engl J Med , vol.371 , pp. 1507-1517
    • Maude, S.L.1    Frey, N.2    Shaw, P.A.3
  • 26
    • 84923019006 scopus 로고    scopus 로고
    • T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial
    • Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet Lond Engl 2015; 385:517-528.
    • (2015) Lancet Lond Engl , vol.385 , pp. 517-528
    • Lee, D.W.1    Kochenderfer, J.N.2    Stetler-Stevenson, M.3
  • 27
    • 84888226232 scopus 로고    scopus 로고
    • T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
    • Mardiros A, Santos CD, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013; 122:3138-3148.
    • (2013) Blood , vol.122 , pp. 3138-3148
    • Mardiros, A.1    Santos, C.D.2    McDonald, T.3
  • 28
    • 84876163922 scopus 로고    scopus 로고
    • Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
    • Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013; 161:389- 401.
    • (2013) Br J Haematol , vol.161 , pp. 389-401
    • Tettamanti, S.1    Marin, V.2    Pizzitola, I.3
  • 29
    • 84905714921 scopus 로고    scopus 로고
    • Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
    • Pizzitola I, Anjos-Afonso F, Rouault-Pierre K, et al. Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo. Leukemia 2014; 28:1596-1605.
    • (2014) Leukemia , vol.28 , pp. 1596-1605
    • Pizzitola, I.1    Anjos-Afonso, F.2    Rouault-Pierre, K.3
  • 30
    • 84901703340 scopus 로고    scopus 로고
    • Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
    • Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 2014; 123:2343-2354.
    • (2014) Blood , vol.123 , pp. 2343-2354
    • Gill, S.1    Tasian, S.K.2    Ruella, M.3
  • 31
    • 0032722187 scopus 로고    scopus 로고
    • Correlation between IL-3 receptor expression and growth potential of human CD34 hematopoietic cells from different tissues
    • Huang S, Chen Z, Yu JF, et al. Correlation between IL-3 receptor expression and growth potential of human CD34 hematopoietic cells from different tissues. Stem Cells Dayt Ohio 1999; 17:265-272.
    • (1999) Stem Cells Dayt Ohio , vol.17 , pp. 265-272
    • Huang, S.1    Chen, Z.2    Yu, J.F.3
  • 32
    • 79955517235 scopus 로고    scopus 로고
    • CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
    • Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 2011; 121:1822-1826.
    • (2011) J Clin Invest , vol.121 , pp. 1822-1826
    • Savoldo, B.1    Ramos, C.A.2    Liu, E.3
  • 33
    • 80051589534 scopus 로고    scopus 로고
    • A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
    • Wang X, Chang W-C, Wong CW, et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 2011; 118:1255-1263.
    • (2011) Blood , vol.118 , pp. 1255-1263
    • Wang, X.1    Chang, W.-C.2    Wong, C.W.3
  • 34
    • 84879409907 scopus 로고    scopus 로고
    • Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation
    • Kharfan-Dabaja MA, Lazarus HM, Nishihori T, et al. Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: A focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 2013; 19:1006-1012.
    • (2013) Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant , vol.19 , pp. 1006-1012
    • Kharfan-Dabaja, M.A.1    Lazarus, H.M.2    Nishihori, T.3
  • 35
    • 84874536909 scopus 로고    scopus 로고
    • Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study
    • Pagano L, Valentini CG, Pulsoni A, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: An Italian multicenter study. Haematologica 2013; 98:239-246.
    • (2013) Haematologica , vol.98 , pp. 239-246
    • Pagano, L.1    Valentini, C.G.2    Pulsoni, A.3
  • 36
    • 84896335556 scopus 로고    scopus 로고
    • Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
    • Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6:224-25.
    • (2014) Sci Transl Med , vol.6 , pp. 224-225
    • Davila, M.L.1    Riviere, I.2    Wang, X.3
  • 37
    • 84920693049 scopus 로고    scopus 로고
    • Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia
    • Wang Q, Wang Y, Lv H, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther J Am Soc Gene Ther 2015; 23:184- 191.
    • (2015) Mol Ther J Am Soc Gene Ther , vol.23 , pp. 184-191
    • Wang, Q.1    Wang, Y.2    Lv, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.